Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception.
Steroid regimens containing androgens are being evaluated currently as hormonal contraceptives for men. The possible non-reproductive effects of such treatment were assessed during an efficacy trial using a prototype regime of 200 mg testosterone enanthate i.m. weekly. Prostatic function and size were monitored by regular rectal examination, blood levels of prostate-specific androgen (PSA) were measured in 30 men and prostatic size was measured by trans-rectal ultrasound imaging in a representative subgroup of five subjects for 12 months and for a further 6 months after discontinuation. Despite the sustained rise in serum levels of testosterone, oestradiol and dihydrotestosterone during treatment, there was no detectable increase in prostatic size on rectal examination or any significant change in blood concentrations of PSA. A small but significant increase (14.3 +/- 2.0%) in maximal prostate transverse area was observed in four men while the remaining one showed no change. Our preliminary data demonstrate the feasibility and importance of monitoring prostatic function in the development of androgen-containing male hormonal contraceptives.
Wallace
E M
EM
MRC Reproductive Biology Unit, Edinburgh, Scotland, U.K.
Pye
S D
SD
Wild
S R
SR
Wu
F C
FC
D000328:Adult; D003272:Contraceptive Agents, Male / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010173:Palpation; D011467:Prostate / Q000000981:diagnostic imaging / Q000187:drug effects*; D017430:Prostate-Specific Antigen / Q000097:blood*; D013739:Testosterone / Q000031:analogs & derivatives* / Q000494:pharmacology; D014463:Ultrasonography
D003272:Contraceptive Agents, Male; D013739:Testosterone; C004648:testosterone enanthate; D017430:Prostate-Specific Antigen